Figure 1.
Overall survival between FLT3-ITD+ AML and FLT3-ITD–AML stratified based on treatment-intensive chemotherapy (blue) or HMA-based therapy (red).

Overall survival between FLT3-ITD+ AML and FLT3-ITD–AML stratified based on treatment-intensive chemotherapy (blue) or HMA-based therapy (red).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal